Training site staff on clinical trial protocols takes time and money, and poor training modules can lead to low compliance or staff that is technically trained, but have missed the learning objectives. Effective training using rich and varied content, leveraging highly engaging methodology and comprehension checks will provide learners with confidence and retention long after the training is completed. Learn more about what you need to reduce risk, increase compliance and enhance quality with a comprehensive training solution ..read more

As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.  ..read more

ICON recently attended the PHUSE US Connect Conference, which took place from February 25th to 28th in Bethesda, Maryland, participating in exhibitions, unique presentations and interactive discussions on key topics. ICON’s experts shared their insights in multiple presentations within the statistical programming sphere ..read more

ICON is leading the way in rare disease clinical research having supported 778 rare disease clinical trials in the past five years. Every day, thousands of colleagues at ICON work tirelessly to support the success of rare disease clinical research – because patients can’t wait ..read more

ICON employees share their experience with Rare Diseases ..read more

ICON participated in the 17th annual Indian Society for Clinical Research (ISCR) conference on the 1-3 February in Hyderabad, India. ICON experts shared insights on topics of special interest including clinical data management and biostatistics and statistical programming, among others ..read more

Difficulties in research and development for rare disease therapeutics have been compounded by a historically challenging market for biotechs. ICON experts share how biotechs can maximise funding for rare disease therapeutic development in our blog ..read more

Physical- and mental-health measure declines are 2 factors likely to impact the healthcare industry as they move forward in 2024 and beyond. Not surprisingly, concerns over rising healthcare costs and how to best control them continue to dominate in significance ..read more

In addition to physical health indicators, mental health declines also serve as a measure of the serious health concerns to the healthcare industry in the United States. These changes likely impact drug manufacturers directly and indirectly through market needs, opportunities, and resource allocations related to the development and marketing of both existing and prospective treatments.  ..read more

When discussing the 5 biggest challenges that await the healthcare industry in 2024, US politics is a key issue. America is clearly divided on many issues, including those involving government spending, healthcare reimbursements, and treatment coverage issues ..read more